Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 11:11AM ET
1.95
Dollar change
+0.01
Percentage change
0.52
%
Index- P/E- EPS (ttm)-0.36 Insider Own35.79% Shs Outstand78.46M Perf Week-1.52%
Market Cap157.60M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float51.89M Perf Month-2.01%
Income-29.12M PEG- EPS next Q-0.13 Inst Own22.46% Short Float0.41% Perf Quarter2.63%
Sales11.16M P/S14.12 EPS this Y-22.95% Inst Trans-2.73% Short Ratio1.28 Perf Half Y37.32%
Book/sh0.46 P/B4.23 EPS next Y-14.88% ROA-19.07% Short Interest0.22M Perf Year12.07%
Cash/sh1.37 P/C1.42 EPS next 5Y- ROE-57.26% 52W Range1.11 - 3.29 Perf YTD-1.52%
Dividend Est.- P/FCF- EPS past 5Y21.74% ROI-55.94% 52W High-40.73% Beta0.34
Dividend TTM- Quick Ratio3.11 Sales past 5Y44.49% Gross Margin- 52W Low75.68% ATR (14)0.12
Dividend Ex-Date- Current Ratio3.11 EPS Y/Y TTM56.72% Oper. Margin-327.47% RSI (14)43.51 Volatility4.43% 5.90%
Employees- Debt/Eq0.51 Sales Y/Y TTM210.56% Profit Margin-260.84% Recom1.43 Target Price4.24
Option/ShortYes / Yes LT Debt/Eq0.38 EPS Q/Q14.01% Payout- Rel Volume0.25 Prev Close1.94
Sales Surprise72.18% EPS Surprise18.33% Sales Q/Q587.25% EarningsMay 09 BMO Avg Volume168.11K Price1.95
SMA20-1.43% SMA50-8.45% SMA2007.95% Trades Volume12,529 Change0.52%
Date Action Analyst Rating Change Price Target Change
Nov-08-23Upgrade Chardan Capital Markets Neutral → Buy $2
Mar-30-23Upgrade JMP Securities Mkt Perform → Mkt Outperform $1.50 → $5
Dec-22-22Upgrade Cantor Fitzgerald Neutral → Overweight $0.80 → $5
Feb-14-22Downgrade Citigroup Buy → Neutral $37 → $1.70
Feb-11-22Downgrade Stifel Buy → Hold $20 → $3
Feb-11-22Downgrade Raymond James Strong Buy → Mkt Perform
Feb-01-22Initiated Raymond James Strong Buy $19
May-03-21Initiated Stifel Buy $20
Mar-25-21Reiterated Citigroup Buy $33 → $44
Nov-03-20Resumed Cantor Fitzgerald Overweight $22
May-09-24 07:00AM
May-08-24 08:00AM
Apr-23-24 07:00AM
Apr-22-24 04:31PM
Apr-19-24 07:00AM
07:00AM Loading…
Mar-13-24 07:00AM
Feb-15-24 07:00AM
Jan-19-24 07:00AM
Jan-05-24 07:00AM
Dec-28-23 08:44AM
Dec-08-23 07:30AM
Nov-07-23 07:00AM
Nov-06-23 07:00AM
Sep-28-23 08:00AM
Sep-27-23 07:00AM
08:00AM Loading…
Sep-07-23 08:00AM
Aug-08-23 06:37AM
Aug-03-23 07:00AM
Aug-01-23 07:00AM
Jul-06-23 07:00AM
Jun-28-23 06:02AM
May-18-23 07:02AM
May-16-23 07:00AM
May-09-23 08:00AM
Apr-20-23 08:00AM
Apr-18-23 08:00AM
Mar-29-23 12:30PM
08:00AM
Mar-14-23 08:00AM
Mar-07-23 08:00AM
08:00AM Loading…
Feb-28-23 08:00AM
Feb-01-23 05:11AM
Dec-29-22 11:36AM
Dec-23-22 12:14PM
Dec-22-22 09:12AM
08:53AM
06:15AM
06:00AM
05:28AM
Nov-14-22 04:30PM
Nov-11-22 05:54AM
Nov-09-22 08:25AM
07:00AM
Nov-03-22 07:00AM
Aug-12-22 02:05PM
Aug-11-22 02:48PM
07:00AM
Aug-04-22 10:25AM
07:00AM
Jul-08-22 07:06AM
Jun-28-22 07:00AM
Jun-01-22 07:00AM
May-09-22 07:00AM
May-05-22 08:15PM
04:30PM
May-03-22 09:55AM
Apr-28-22 03:02PM
Apr-26-22 04:10PM
Apr-19-22 04:30PM
Apr-13-22 09:49AM
07:00AM
Apr-12-22 04:30PM
Apr-04-22 07:00AM
Mar-23-22 04:30PM
Mar-07-22 07:00AM
Feb-24-22 08:35AM
07:00AM
Feb-17-22 03:02PM
Feb-14-22 06:23PM
04:38PM
Feb-11-22 01:24PM
07:00AM
Feb-10-22 07:19PM
Feb-07-22 04:30PM
Feb-02-22 02:11AM
Jan-04-22 07:00AM
Dec-30-21 07:00AM
Dec-16-21 07:00AM
Nov-18-21 04:01PM
Nov-11-21 07:00AM
Nov-08-21 04:30PM
Nov-04-21 10:05AM
07:00AM
Oct-19-21 10:44AM
Oct-04-21 08:00AM
Sep-13-21 08:32AM
Sep-10-21 05:16AM
Sep-09-21 12:01PM
06:58AM
Sep-08-21 04:15PM
04:01PM
Sep-06-21 04:15PM
Sep-03-21 08:00AM
Aug-11-21 04:30PM
Aug-05-21 08:45AM
07:00AM
Jul-26-21 10:59AM
Jul-19-21 08:38AM
Jun-10-21 07:00AM
May-18-21 07:32AM
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.